Advanced Glycation End Products in Neurodegenerative Diseases
Advanced glycation end products (AGEs) have attracted interest as therapeutic targets for neurodegenerative diseases. AGEs facilitate the onset and progression of various neurogenerative disorders due to their ability to promote cross-linking and aggregation of proteins. Further, the interaction bet...
Gespeichert in:
| Veröffentlicht in: | Journal of molecular neuroscience 2024-12, Vol.74 (4), p.114, Article 114 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 114 |
| container_title | Journal of molecular neuroscience |
| container_volume | 74 |
| creator | Raghavan, Cibin T. |
| description | Advanced glycation end products (AGEs) have attracted interest as therapeutic targets for neurodegenerative diseases. AGEs facilitate the onset and progression of various neurogenerative disorders due to their ability to promote cross-linking and aggregation of proteins. Further, the interaction between AGEs and receptor for AGEs (RAGE) activates neuroinflammatory, oxidative stress and excitotoxicity processes that contribute to neuronal cell death. Various therapeutic efforts have targeted lowering the production of AGEs, inhibiting RAGE or inhibiting some of the processes of the AGE-RAGE axis as potential treatments for these disorders. Whereas effective treatments for many neurodegenerative disorders remain elusive, such efforts offer promise to slow the progression of diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). |
| doi_str_mv | 10.1007/s12031-024-02297-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146609098</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3142389629</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-50295c4d73031007eba273125461ee1c4b2d5aa6e14c3d6b00a271cc430363573</originalsourceid><addsrcrecordid>eNp9kD9PwzAQxS0EoqXwBRhQJBaWgM-OnXpgqEopSBUwwGw5zrVKlSbFTir12-OS8kcMDCefdb979_QIOQd6DZSmNx4Y5RBTloRiKo3hgPRBCBUDSHn4q--RE--XlDJIYHhMelxJwVWq-uR2lG9MZTGPpuXWmqaoq2hS5dGLq_PWNj4qqugJ2_DDBVboArHB6K7waDz6U3I0N6XHs_07IG_3k9fxQzx7nj6OR7PYMiGbWFCmhE3ylAe_wTlmhqUcmEgkIIJNMpYLYyRCYnkuM0rDHKxNAi-5SPmAXHW6a1e_t-gbvSq8xbI0Fdat1xwSKamiahjQyz_osm5dFdztKMaHSjIVKNZR1tXeO5zrtStWxm01UL2zqLtwdQhXf4arISxd7KXbbIX598pXmgHgHeDDqFqg-7n9j-wHzVuB8g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3142389629</pqid></control><display><type>article</type><title>Advanced Glycation End Products in Neurodegenerative Diseases</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Raghavan, Cibin T.</creator><creatorcontrib>Raghavan, Cibin T.</creatorcontrib><description>Advanced glycation end products (AGEs) have attracted interest as therapeutic targets for neurodegenerative diseases. AGEs facilitate the onset and progression of various neurogenerative disorders due to their ability to promote cross-linking and aggregation of proteins. Further, the interaction between AGEs and receptor for AGEs (RAGE) activates neuroinflammatory, oxidative stress and excitotoxicity processes that contribute to neuronal cell death. Various therapeutic efforts have targeted lowering the production of AGEs, inhibiting RAGE or inhibiting some of the processes of the AGE-RAGE axis as potential treatments for these disorders. Whereas effective treatments for many neurodegenerative disorders remain elusive, such efforts offer promise to slow the progression of diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD).</description><identifier>ISSN: 1559-1166</identifier><identifier>ISSN: 0895-8696</identifier><identifier>EISSN: 1559-1166</identifier><identifier>DOI: 10.1007/s12031-024-02297-1</identifier><identifier>PMID: 39653979</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Advanced glycosylation end products ; Age ; Alzheimer's disease ; Amyotrophic lateral sclerosis ; Animals ; Biomedical and Life Sciences ; Biomedicine ; Cell Biology ; Cell cycle ; Cell death ; Crosslinking ; Excitotoxicity ; Glucose ; Glycation End Products, Advanced - metabolism ; Humans ; Huntington's disease ; Huntingtons disease ; Immunoglobulins ; Kinases ; Ligands ; Movement disorders ; Neurochemistry ; Neurodegeneration ; Neurodegenerative diseases ; Neurodegenerative Diseases - metabolism ; Neurology ; Neurosciences ; Oxidation ; Oxidative stress ; Parkinson's disease ; Proteins ; Proteomics ; Receptor for Advanced Glycation End Products - metabolism ; Review ; Therapeutic targets</subject><ispartof>Journal of molecular neuroscience, 2024-12, Vol.74 (4), p.114, Article 114</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>Copyright Springer Nature B.V. Dec 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-50295c4d73031007eba273125461ee1c4b2d5aa6e14c3d6b00a271cc430363573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12031-024-02297-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12031-024-02297-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39653979$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raghavan, Cibin T.</creatorcontrib><title>Advanced Glycation End Products in Neurodegenerative Diseases</title><title>Journal of molecular neuroscience</title><addtitle>J Mol Neurosci</addtitle><addtitle>J Mol Neurosci</addtitle><description>Advanced glycation end products (AGEs) have attracted interest as therapeutic targets for neurodegenerative diseases. AGEs facilitate the onset and progression of various neurogenerative disorders due to their ability to promote cross-linking and aggregation of proteins. Further, the interaction between AGEs and receptor for AGEs (RAGE) activates neuroinflammatory, oxidative stress and excitotoxicity processes that contribute to neuronal cell death. Various therapeutic efforts have targeted lowering the production of AGEs, inhibiting RAGE or inhibiting some of the processes of the AGE-RAGE axis as potential treatments for these disorders. Whereas effective treatments for many neurodegenerative disorders remain elusive, such efforts offer promise to slow the progression of diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD).</description><subject>Advanced glycosylation end products</subject><subject>Age</subject><subject>Alzheimer's disease</subject><subject>Amyotrophic lateral sclerosis</subject><subject>Animals</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cell Biology</subject><subject>Cell cycle</subject><subject>Cell death</subject><subject>Crosslinking</subject><subject>Excitotoxicity</subject><subject>Glucose</subject><subject>Glycation End Products, Advanced - metabolism</subject><subject>Humans</subject><subject>Huntington's disease</subject><subject>Huntingtons disease</subject><subject>Immunoglobulins</subject><subject>Kinases</subject><subject>Ligands</subject><subject>Movement disorders</subject><subject>Neurochemistry</subject><subject>Neurodegeneration</subject><subject>Neurodegenerative diseases</subject><subject>Neurodegenerative Diseases - metabolism</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Oxidation</subject><subject>Oxidative stress</subject><subject>Parkinson's disease</subject><subject>Proteins</subject><subject>Proteomics</subject><subject>Receptor for Advanced Glycation End Products - metabolism</subject><subject>Review</subject><subject>Therapeutic targets</subject><issn>1559-1166</issn><issn>0895-8696</issn><issn>1559-1166</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD9PwzAQxS0EoqXwBRhQJBaWgM-OnXpgqEopSBUwwGw5zrVKlSbFTir12-OS8kcMDCefdb979_QIOQd6DZSmNx4Y5RBTloRiKo3hgPRBCBUDSHn4q--RE--XlDJIYHhMelxJwVWq-uR2lG9MZTGPpuXWmqaoq2hS5dGLq_PWNj4qqugJ2_DDBVboArHB6K7waDz6U3I0N6XHs_07IG_3k9fxQzx7nj6OR7PYMiGbWFCmhE3ylAe_wTlmhqUcmEgkIIJNMpYLYyRCYnkuM0rDHKxNAi-5SPmAXHW6a1e_t-gbvSq8xbI0Fdat1xwSKamiahjQyz_osm5dFdztKMaHSjIVKNZR1tXeO5zrtStWxm01UL2zqLtwdQhXf4arISxd7KXbbIX598pXmgHgHeDDqFqg-7n9j-wHzVuB8g</recordid><startdate>20241210</startdate><enddate>20241210</enddate><creator>Raghavan, Cibin T.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20241210</creationdate><title>Advanced Glycation End Products in Neurodegenerative Diseases</title><author>Raghavan, Cibin T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-50295c4d73031007eba273125461ee1c4b2d5aa6e14c3d6b00a271cc430363573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Advanced glycosylation end products</topic><topic>Age</topic><topic>Alzheimer's disease</topic><topic>Amyotrophic lateral sclerosis</topic><topic>Animals</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cell Biology</topic><topic>Cell cycle</topic><topic>Cell death</topic><topic>Crosslinking</topic><topic>Excitotoxicity</topic><topic>Glucose</topic><topic>Glycation End Products, Advanced - metabolism</topic><topic>Humans</topic><topic>Huntington's disease</topic><topic>Huntingtons disease</topic><topic>Immunoglobulins</topic><topic>Kinases</topic><topic>Ligands</topic><topic>Movement disorders</topic><topic>Neurochemistry</topic><topic>Neurodegeneration</topic><topic>Neurodegenerative diseases</topic><topic>Neurodegenerative Diseases - metabolism</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Oxidation</topic><topic>Oxidative stress</topic><topic>Parkinson's disease</topic><topic>Proteins</topic><topic>Proteomics</topic><topic>Receptor for Advanced Glycation End Products - metabolism</topic><topic>Review</topic><topic>Therapeutic targets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raghavan, Cibin T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of molecular neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raghavan, Cibin T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advanced Glycation End Products in Neurodegenerative Diseases</atitle><jtitle>Journal of molecular neuroscience</jtitle><stitle>J Mol Neurosci</stitle><addtitle>J Mol Neurosci</addtitle><date>2024-12-10</date><risdate>2024</risdate><volume>74</volume><issue>4</issue><spage>114</spage><pages>114-</pages><artnum>114</artnum><issn>1559-1166</issn><issn>0895-8696</issn><eissn>1559-1166</eissn><abstract>Advanced glycation end products (AGEs) have attracted interest as therapeutic targets for neurodegenerative diseases. AGEs facilitate the onset and progression of various neurogenerative disorders due to their ability to promote cross-linking and aggregation of proteins. Further, the interaction between AGEs and receptor for AGEs (RAGE) activates neuroinflammatory, oxidative stress and excitotoxicity processes that contribute to neuronal cell death. Various therapeutic efforts have targeted lowering the production of AGEs, inhibiting RAGE or inhibiting some of the processes of the AGE-RAGE axis as potential treatments for these disorders. Whereas effective treatments for many neurodegenerative disorders remain elusive, such efforts offer promise to slow the progression of diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD).</abstract><cop>New York</cop><pub>Springer US</pub><pmid>39653979</pmid><doi>10.1007/s12031-024-02297-1</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1559-1166 |
| ispartof | Journal of molecular neuroscience, 2024-12, Vol.74 (4), p.114, Article 114 |
| issn | 1559-1166 0895-8696 1559-1166 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3146609098 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Advanced glycosylation end products Age Alzheimer's disease Amyotrophic lateral sclerosis Animals Biomedical and Life Sciences Biomedicine Cell Biology Cell cycle Cell death Crosslinking Excitotoxicity Glucose Glycation End Products, Advanced - metabolism Humans Huntington's disease Huntingtons disease Immunoglobulins Kinases Ligands Movement disorders Neurochemistry Neurodegeneration Neurodegenerative diseases Neurodegenerative Diseases - metabolism Neurology Neurosciences Oxidation Oxidative stress Parkinson's disease Proteins Proteomics Receptor for Advanced Glycation End Products - metabolism Review Therapeutic targets |
| title | Advanced Glycation End Products in Neurodegenerative Diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T04%3A42%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advanced%20Glycation%20End%20Products%20in%20Neurodegenerative%20Diseases&rft.jtitle=Journal%20of%20molecular%20neuroscience&rft.au=Raghavan,%20Cibin%20T.&rft.date=2024-12-10&rft.volume=74&rft.issue=4&rft.spage=114&rft.pages=114-&rft.artnum=114&rft.issn=1559-1166&rft.eissn=1559-1166&rft_id=info:doi/10.1007/s12031-024-02297-1&rft_dat=%3Cproquest_cross%3E3142389629%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3142389629&rft_id=info:pmid/39653979&rfr_iscdi=true |